| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5669 | Zwm026 | Novel multi-target inhibitor, harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR |
|
| DCC5670 | Zxh-1-161 Featured | Novel Selective Degrader of GSPT1 |
|
| DCC5671 | Zx-j-19j | Novel inhibitor of Cyclophilin J (CyPJ) PPIase, demonstrating remarkable inhibition of tumor cell growth, comparable to CsA but much stronger than 5-fluorouracil |
|
| DCC5672 | Zx-j-19l | Novel inhibitor of Cyclophilin J (CyPJ) PPIase, demonstrating remarkable inhibition of tumor cell growth, comparable to CsA but much stronger than 5-fluorouracil |
|
| DCC5673 | Zxx2-77 | Cyclooxygenase-1 inhibitor |
|
| DCC5674 | Zydpla1 | Novel next generation orally active DPP-4 inhibitor to treat Type 2 Diabetes |
|
| DCC5675 | Zyj-25e | Novel histone deacetylase inhibitor (HDACi) with potent oral antitumor activities |
|
| DCC5676 | Zyj-34c | Novel histone deacetylase inhibitor (HDACi) with potent oral antitumor activities |
|
| DCC5677 | Zyj-34v | Oral active histone deacetylase inhibitor with potent antitumor activity |
|
| DCC5678 | Zyz-803 | Novel slow H2S-NO-releasing hybrid, attenuating cardiac dysfunction after heart failure |
|
| DC65731 | DPPA Featured | DPPA is a form of phosphatidic acid (PA). |
|
| DC72914 | UE2343 | UE2343 (UE-2343, Xanamem) is a potent, orally bioavailable, brain penetrant 11β-HSD1 inhibitor with IC50 of 24 nM in cell-free assays, with no activity for isozyme 11β-HSD2. |
|
| DC72915 | AM4085 | AM4085 is a potent, orally bioavailable lectin domain of FmLH antagonist with IC50 of 0.19 uM. |
|
| DC72916 | BB2-50F | BB2-50F is a bactericidal inhibitor of M. tuberculosis with MIC value of 8 uM (H37Rv), inhibits succinate dehydrogenase and the F1Fo-ATP synthase. |
|
| DC72917 | BDM71339 | BDM71339 is the first small molecule inhibitor of mycobacterial transcriptional regulator EthR, boosts ten times the activity of ethionamide in TB-infected macrophages at low nanomolar concentrations (EC50=72 nM) in vitro. |
|
| DC72918 | BDM88855 hydrochloride | BDM88855 Hcl is a novel allosteric efflux-pump inhibitor that potentiate antibiotic activity in E. coli through inhibition of its primary RND transporter, AcrAB-TolC. |
|
| DC72919 | BDM91288 | BDM91288 is a pyridylpiperazine-based AcrB efflux pump inhibitor, potentiate the activity of a panel of antibiotics against K. pneumoniae. |
|
| DC72920 | BFA1 | BFA1 is a specific small-molecule activator of Burkholderia FixLJ signaling pathway, inhibit the virulence of multiple pathogenic Burkholderia species. |
|
| DC72921 | COE2-2hexyl | COE2-2hexyl is a broad-spectrum antibacterial conjugated oligoelectrolyte (COE), does not evoke bacterial resistance, inhibits methicillin-resistant S. aureus (MRSA, MT3302) with MIC of 1 ug/mL. |
|
| DC72922 | Cresomycin | Cresomycin (CRM) is a bridged macrobicyclic antibiotic via inhibiting bacterial ribosome, shows broad efficacy of CRM against clinical isolates of MDR Gram-negative pathogens differentiates the synthetic macrobicyclic class from traditional lincosamides. |
|
| DC72923 | CUO246 | CUO246 (CUO-246) is a potent, selective bacterial DNA gyrase/topoisomerase IV inhibitor, CUO246 is active in vitro against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens. |
|
| DC72924 | D66 | D66 is a specific small molecule that disrupts S. Typhimurium membrane voltage without cell lysis, prevents S. Typhimurium survival in macrophages (IC50=6.0 uM) and inhibits bacterial growth under conditions that compromise the cell envelope. |
|
| DC72925 | DS01750413 | DS01750413 is a novel FtsZ inhibitor and new derivative of PC190723 (Cat. PC-47012), inhibits S. aureus FtsZ protein with IC50 of 2 mg/L, has an IC50 of 0.03 mg/L in cell elongation assay of B. subtilis. |
|
| DC72926 | EPM35 | EPM35 (Efflux pump modulator 35) is a small molecule that bind AcrB (KD=0.29 uM), inhibit AcrAB-TolC and modulates bacterial efflux pump activity, reduces bacterial intracellular load. |
|
| DC72927 | GSK030 | GSK030 (GSK3212030A) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites. |
|
| DC72928 | GSK147 | GSK147 (GSK-147) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=40 nM). |
|
| DC72929 | GSK692 | GSK692 (GSK-692) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=10 nM). |
|
| DC72930 | HR3744 | HR3744 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 10 uM in saeP1 promoter assays, reduces expression of hla and other virulence factors. |
|
| DC72931 | HSGN-189 | HSGN-189 is a potent lipoteichoic acid (LTA) biosynthesis inhibitor, exhibits potent antibacterial activity against both MRSA and VRE strains with MICs of 1 ug/mL. |
|
| DC72932 | IITR06144 | IITR06144 is a novel nitrofuran and exhibits broad-spectrum bactericidal activity against most MDR bacteria (MIC, 0.5 mg/mL). |
|
